| Literature DB >> 27333829 |
Simon Meyer1, Catherine Giannopoulou1, Delphine Courvoisier2, Martin Schimmel3, Frauke Müller1, Andrea Mombelli1.
Abstract
OBJECTIVES: To compare in persons aged 70 years or older the clinical and inflammatory changes occurring around implants and natural teeth during and after a phase of undisturbed plaque accumulation.Entities:
Keywords: adult; aged; biomarkers; dental implants; gingival crevicular fluid; gingivitis; mucositis; oral hygiene
Mesh:
Substances:
Year: 2016 PMID: 27333829 PMCID: PMC5599942 DOI: 10.1111/clr.12912
Source DB: PubMed Journal: Clin Oral Implants Res ISSN: 0905-7161 Impact factor: 5.977
Protocol of the study
| Preparatory phase | Plaque accumulation | Oral hygiene | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Pre‐baseline) | Visit 2 (Baseline) | Visit 3 (PS<20%) | Visit 4 (Day 0, no hygiene) | Visit 5 (Day 7, no hygiene) | Visit 6 (Day 14, no hygiene) | Visit 7 (Day 21, no hygiene) | Visit 8 (Day 28, PS<20%) | Visit 9 (Day 42, PS<20%) | |
| Subject screening | X | ||||||||
| Informed consent | X | ||||||||
| Health history, medications | X | X | X | X | X | X | X | X | X |
| Professional plaque removal | X | X | X | X | X | X | |||
| Oral hygiene reinforcement | X | X | X | X | X | ||||
| GCF/PCF sampling | X | X | X | X | X | X | X | ||
| PS | X | X | X | X | X | ||||
| PD, BOP, REC | X | X | X | X | |||||
| PI, GI | X | X | X | X | X | X | X | X | |
Clinical and biological characteristics at the selected study teeth and implants for 20 participants at baseline, expressed as median and interquartile range [IQR]
| Teeth | Implants |
| |
|---|---|---|---|
| Mean PI | 0.46 [0.15; 0.77] | 0.04 [0.00; 0.33] | 0.007 |
| Mean GI | 0.00 [0.00; 0.08] | 0.00 [0.00; 0.08] | 0.60 |
| Mean PD, mm | 2.42 [2.21; 2.54] | 2.96 [2.75; 3.13] | <0.001 |
| Mean BOP | 0.08 [0.00; 0.17] | 0.17 [0.08; 0.19] | 0.07 |
| Mean REC, mm | 1.17 [0.81; 1.75] | 0.36 [0.00; 0.83] | 0.002 |
| IL‐1β, pg/ml | 145.8 [44.5; 221.7] | 89.6 [42.3; 186.6] | 0.79 |
| IL‐1ra, pg/ml | 47.4 [27.1; 508.9] | 52.6 [25.0; 512.4] | 0.89 |
| IL‐6, pg/ml | 2.4 [1.4; 12.4] | 1.5 [1.1; 6.9] | 0.27 |
| IL‐8, pg/ml | 422.4 [304.3; 681.5] | 481.9 [362.3; 870.8] | 0.07 |
| IL‐17, pg/ml | 25.6 [18.3; 31.3] | 25.4 [21.9; 38.4] | 0.29 |
| Basic‐FGF, pg/ml | 29.6 [26.8; 32.4] | 31.6 [28.9; 38.1] | 0.12 |
| G‐CSF, pg/ml | 716.9 [195.8; 1136.0] | 485.2 [121.5; 904.2] | 0.24 |
| GM‐CSF, pg/ml | 43.9 [31.2; 49.1] | 47.3 [30.0; 49.8] | 0.52 |
| IFN‐γ, pg/ml | 118.3 [86.6; 144.4] | 127.2 [94.5; 165.3] | 0.20 |
| MIP‐1β, pg/ml | 13.4 [7.3; 26.8] | 19.8 [10.9; 42.1] | 0.06 |
| TNF‐α, pg/ml | 13.0 [7.3; 19.9] | 12.2 [9.1; 22.6] | 0.07 |
| VEGF, pg/ml | 338.6 [231.5; 636.4] | 422.5 [334.3; 593.4] | 0.30 |
Difference between groups.
Figure 1Clinical status of one participant after 21 days without oral hygiene, showing plaque accumulation and gingivitis.
Clinical parameters before (day 0), during (days 7, 14, 21) and after plaque accumulation (days 28, 42), expressed as median and interquartile range [IQR]. The GI is dichotomized as 0 or 1 vs. 2 or 3 (GI >1)
| Plaque accumulation | Oral hygiene | |||||
|---|---|---|---|---|---|---|
| Day 0 | Day 7 | Day 14 | Day 21 | Day 28 | Day 42 | |
| Teeth | ||||||
| Mean PI | 0.00 [0.00; 0.08] |
|
|
|
|
|
| GI >1 | 0.00 [0.00; 0.00] | 0.17 [0.17; 0.33] | 0.42 [0.25; 0.60] |
|
| 0.00 [0.00; 0.02] |
| Mean PD [mm] |
| – | – |
| – |
|
| Mean BOP | 0.00 [0.00; 0.02] | – | – |
| – | 0.04 [0.00; 0.08] |
| Mean REC [mm] |
| – | – |
| – |
|
| Implants | ||||||
| Mean PI | 0.00 [0.00; 0.00] |
|
|
|
|
|
| GI >1 | 0.00 [0.00; 0.00] | 0.25 [0.17; 0.42] | 0.46 [0.31; 0.60] |
|
| 0.00 [0.00; 0.00] |
| Mean PD [mm] |
| – | – |
| – |
|
| Mean BOP | 0.00 [0.00; 0.10] | – | – |
| – | 0.00 [0.00; 0.17] |
| Mean REC [mm] |
| – | – |
| – |
|
Significant difference when compared with value at day 0 (P < 0.05).
Values in bold: significant difference between implants and teeth (P < 0.05).
Figure 2Average proportion of sites with PI of 1, 2, and 3. EXM: experimental phase with no oral hygiene; T: teeth; I: implants.
Figure 3Average proportion of sites with GI of 1, 2, and 3. EXM: experimental phase with no oral hygiene; T: teeth; I: implants.
Figure 4Proportion of sites with GI >1, from baseline to the end of follow‐up time, for each participant. EXM: experimental phase with no oral hygiene.
Biomarkers before (day 0), during (days 7, 14, 21) and after plaque accumulation (days 28, 42). Concentrations are expressed in pg/ml and are median [IQR]
| Plaque accumulation | Oral hygiene | |||||
|---|---|---|---|---|---|---|
| Day 0 | Day 7 | Day 14 | Day 21 | Day 28 | Day 42 | |
| Teeth | ||||||
| IL‐1β | 87.3 [50.6; 115.1] |
|
|
| 103.7 [50.1; 205.1] | 88.5 [41.4; 208.8] |
| IL‐1ra | 45.6 [26.8; 89.2] | 108.2 [71.3; 163.1] | 68.6 [49.3; 111.5] | 66.6 [35.4; 177.0] | 61.3 [27.5; 408.6] |
|
| IL‐6 |
| 1.8 [0.7; 2.6] | 1.7 [1.0; 3.0] | 1.1 [0.7; 2.5] | 1.3 [0.5; 3.1] | 2.6 [0.8; 4.3] |
| IL‐8 | 429.3 [302.6; 528.2] |
|
| 263.5 [194.9; 348.9] | 299.2 [211.5; 478.4] | 431.3 [219.0; 664.1] |
| IL‐17 | 20.3 [14.3; 29.5] | 18.9 [12.0; 29.2] | 14.6 [0.0; 28.1] | 13.3 [0.0; 30.0] | 11.7 [0.0; 20.8] | 15.2 [6.8; 25.3] |
| Basic‐FGF | 31.7 [27.4; 35.4] | 40.1 [32.3; 45.4] | 38.2 [1.7; 48.4] | 30.8 [3.8; 39.1] | 26.8 [0.0; 34.7] | 30.1 [18.0; 41.3] |
| G‐CSF | 496.1 [107.3; 1115.9] | 443.4 [170.3; 659.5] | 236.4 [170.4; 433.7] | 259.5 [67.7; 661.4] | 273.3 [68.8; 596.3] | 363.7 [29.0; 634.6] |
| GM‐CSF | 31.8 [20.6; 48.4] | 27.3 [16.5; 41.0] | 25.0 [2.6; 40.0] |
| 26.7 [2.5; 39.9] | 30.1 [20.4; 42.3] |
| IFN‐γ | 123.2 [75.5; 140.0] | 111.5 [103.0; 163.9] | 106.1 [47.9; 148.8] |
| 79.2 [15.8; 92.1] | 97.9 [52.9; 116.9] |
| MIP‐1β | 17.8 [7.6; 27.8] |
| 4.7 [2.7; 6.6] |
| 6.1 [4.3; 15.3] | 10.7 [7.9; 18.4] |
| TNF‐α | 11.1 [6.4; 20.5] | 12.8 [8.7; 19.4] | 10.4 [6.3; 18.6] |
| 7.2 [3.2; 11.6] | 8.6 [5.7; 24.1] |
| VEGF | 391.0 [260.8; 470.6] | 339.7 [293.2; 558.2] | 351.2 [284.0; 528.4] | 317.8 [244.1; 725.0] | 235.8 [138.1; 368.3] | 340.8 [159.3; 474.3] |
| Implants | ||||||
| IL‐1β | 80.9 [38.0; 146.0] |
|
|
| 81.7 [44.2; 132.2] | 86.1 [62.5; 228.2] |
| IL‐1ra | 61.5 [31.5; 213.5] | 125.1 [36.7; 186] | 103.0 [50.8; 179.7] | 54.2 [33.6; 119.6] | 75.7 [39.1; 104.6] |
|
| IL‐6 |
| 1.8 [0.83; 2.74] | 1.3 [0.5; 2.4] | 1.6 [0.3; 2.4] | 1.3 [0.9; 2.1] | 1.8 [0.5; 6.6] |
| IL‐8 | 419.8 [232.6; 904.3] |
|
| 231.3 [168.8; 551.9] | 359.3 [220.6; 523.1] | 498.6 [184.6; 823.5] |
| IL‐17 | 19.4 [12.6; 28.9] | 22.1 [9.44; 32.7] | 11.3 [0.0; 30.7] | 3.5 [0.0; 20.6] | 11.8 [0.0; 25.3] | 14.2 [1.5; 23.6] |
| Basic‐FGF | 31.3 [27.0; 35.3] | 37.7 [28.9; 44] | 34.7 [0.01; 52.4] | 19.2 [0.3; 35.7] | 22.0 [0.0; 40.6] | 34.0 [13.9; 36.5] |
| G‐CSF | 257.3 [149.4; 667.0] | 263 [108; 561] | 192.5 [41.0; 404.3] | 65.9 [9.1; 259.8] | 35.9 [8.9; 395.9] | 220.5 [18.3; 432.4] |
| GM‐CSF | 34.2 [20.7; 47.3] | 25.9 [15; 36.5] | 17.2 [2.2; 39.2] |
| 21.0 [2.8; 39.5] | 30.7 [12.3; 40.5] |
| IFN‐γ | 92.4 [80.7; 129.3] | 119 [68.8; 143] | 89.4 [26.8; 140.4] |
| 54.5 [17.1; 104.3] | 92.6 [26.0; 126.4] |
| MIP‐1β | 12.6 [7.1; 26.8] |
| 7.5 [4.8; 19.2] |
| 12.3 [6.1; 24.1] | 12.1 [8.1; 29.4] |
| TNF‐α | 7.1 [5.7; 17.8] | 11.8 [8.12; 17.5] | 9.4 [2.7; 13.2] |
| 7.6 [3.6; 15.8] | 14.6 [3.0; 27.6] |
| VEGF | 400.2 [211.1; 564.8] | 368 [212; 702] | 396.1 [218.2; 645.3] | 328.0 [156.8; 506.5] | 157.1 [127.6; 374.9] | 303.6 [141.6; 444.6] |
Significant difference when compared with value at day 0 (P < 0.05).
Values in bold: significant difference between implants and teeth (P < 0.05).